Clinical Application of 18F-labeled RD2 PET/CT Imaging in the Diagnosis and Treatment of Small Liver Carcinoma

Liver Carcinoma Clinical Trial

Official title:

Clinical Application of 18F-labeled RD2 PET/CT Imaging in the Diagnosis and Treatment of Small Liver Carcinoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05681234
• Other study ID #: LS2021058
• Status: Completed
• Phase: N/A
• Start date: August 24, 2022
• Est. completion date: December 20, 2022

Study information

• Verified date: December 2022
• Source: Affiliated Hospital of Jiangnan University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single arm study to evaluate the safety and biodistribution of 18F-labeled RD2 PET/CT Imaging in patients with small liver carcinoma.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: December 20, 2022
• Est. primary completion date: November 2, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients with highly suspected tumor;

2. Patients underwent PET/CT examination within 1 week;

3. Patients voluntarily signed informed consent;

4. Over 18 years old, male or female.

Exclusion Criteria:

1. Pregnant women;

2. Lactating women;

3. Patients with impaired renal function.

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Hepatocellular
• Liver Carcinoma

Intervention

Radiation:
• 18F-RD2
Patients will receive 5-10 mCi 18F-RD2

Locations

Country	Name	City	State
China	Affiliated Hospital of Jiangnan University	Wuxi	Jiangsu

Sponsors (1)

Lead Sponsor	Collaborator
Affiliated Hospital of Jiangnan University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluation of tissue distribution of 18F-RD2	Biodistribution of 18F-RD2 evaluated by radioactive uptake values (standardized uptake values, SUVs) in various organs during repeated 18F-RD2 scans will be reported.	2 hours